Get the Stockscreener App
44.48
0.34%
0.15
After Hours:
44.86
0.38
+0.85%
Definium Therapeutics Inc stock is traded at $44.48, with a volume of 2.59M.
It is up +0.34% in the last 24 hours and up +88.87% over the past month.
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.
See More
Previous Close:
$44.33
Open:
$44.35
24h Volume:
2.59M
Relative Volume:
0.93
Market Cap:
$5.90B
Revenue:
-
Net Income/Loss:
$-237.54M
P/E Ratio:
-17.77
EPS:
-2.5033
Net Cash Flow:
$-145.05M
1W Performance:
-5.44%
1M Performance:
+88.87%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$42.50
$45.38
1-Week Range:
$42.42
$47.20
52-Week Range:
$14.62
$49.20
Definium Therapeutics Inc Stock (DFTX) Company Profile
Name
Definium Therapeutics Inc
Sector
Industry
Phone
212-220-6633
Address
ONE WORLD TRADE CENTER, NEW YORK
Compare DFTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DFTX
Definium Therapeutics Inc
|
44.48 | 5.88B | 0 | -237.54M | -145.05M | -2.5033 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.94 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Definium Therapeutics Inc Stock (DFTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-17-26 | Initiated | Stifel | Buy |
| Apr-10-26 | Initiated | Piper Sandler | Overweight |
| Feb-24-26 | Initiated | Wolfe Research | Outperform |
| Jan-30-26 | Initiated | Jefferies | Buy |
| Oct-13-25 | Initiated | Needham | Buy |
| Aug-04-25 | Resumed | Oppenheimer | Outperform |
| Jan-28-25 | Initiated | Evercore ISI | Outperform |
| Dec-20-24 | Initiated | Chardan Capital Markets | Buy |
| Oct-14-24 | Resumed | Leerink Partners | Outperform |
| Jul-24-24 | Initiated | ROTH MKM | Buy |
| May-29-24 | Initiated | Robert W. Baird | Outperform |
| Apr-15-24 | Initiated | Leerink Partners | Outperform |
| Dec-05-23 | Initiated | Canaccord Genuity | Buy |
| Dec-09-22 | Resumed | ROTH Capital | Buy |
| Nov-16-22 | Initiated | RBC Capital Mkts | Outperform |
| Aug-26-22 | Initiated | Oppenheimer | Outperform |
| Aug-10-22 | Initiated | Cantor Fitzgerald | Overweight |
| May-04-22 | Initiated | ROTH Capital | Buy |
| Jun-28-21 | Initiated | Maxim Group | Buy |
View All
Definium Therapeutics Inc Stock (DFTX) Latest News
Definium Therapeutics Announces New Employee Inducement Grants - Business Wire
Earnings call transcript: Definium’s Q1 2026 EPS miss overshadows strategic advances - Investing.com
Definium earnings on deck as pivotal psychedelic trial data looms By Investing.com - Investing.com India
DFTXDefinium Therapeutics Inc Volatility & Greeks - Finviz
Enterprise value to EBITDA forward of Definium Therapeutics, Inc. – NASDAQ:DFTX - TradingView
LSD therapy biotech Definium fends off trade-secret lawsuit - Reuters
DFTX Stock Clocks Best Day In Over Two Years On 'Best-Case' Clinical Results For Oral Lysergide In Depression - Stocktwits
Definium Therapeutics (DFTX) Institutional Ownership 2026 - MarketBeat
Definium Therapeutics Completes $805 Million Upsized Public Offering - Global Legal Chronicle
DFTX Maintained by Canaccord Genuity -- Price Target Lowered to $58 - GuruFocus
Hogan Lovells advises Definium Therapeutics, Inc. in Upsized Public Offering - Legal Desire Media and Insights
Is Definium Therapeutics, Inc. (DFTX) Stock Poised for Further Gains After Positive Emerge Trial Update? - Insider Monkey
Top 3 Health Care Stocks That May Keep You Up At Night In June - Benzinga
Canaccord cuts Definium Therapeutics stock price target on share count - Investing.com
CCORF Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Cuts Target Price to $58 - Moomoo
Analysts Are Bullish on Top Healthcare Stocks: Crinetics Pharmaceuticals (CRNX), Definium Therapeutics (DFTX) - The Globe and Mail
Definium Therapeutics stock hits 52-week high at 47.01 USD By Investing.com - Investing.com Nigeria
Definium Therapeutics stock hits 52-week high at 47.01 USD - Investing.com
Definium Therapeutics, Inc.(NasdaqGS:DFTX) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Definium Therapeutics, Inc.(NasdaqGS: DFTX) dropped from Russell 3000E Index - marketscreener.com
Definium Therapeutics, Inc.(NasdaqGS:DFTX) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Definium Therapeutics, Inc.(NasdaqGS: DFTX) dropped from Russell Microcap Index - marketscreener.com
Definium Therapeutics, Inc.(NasdaqGS:DFTX) dropped from Russell 3000 Value Benchmark - marketscreener.com
Definium Therapeutics, Inc.(NasdaqGS:DFTX) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com
10 Best Biotech Stocks to Buy According to Analysts - Insider Monkey
DFTX Vs CMPS: Which Stock Has More Upside From Trump’s New Psychedelic Therapy Push? - Stocktwits
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Definium Therapeutics, Inc.(NasdaqGS:DFTX) dropped from Russell 3000E Value Benchmark - marketscreener.com
Price to sales forward of Definium Therapeutics, Inc. – NASDAQ:DFTX - TradingView
Enterprise value to revenue forward of Definium Therapeutics, Inc. – NASDAQ:DFTX - TradingView
Enterprise value to EBIT forward of Definium Therapeutics, Inc. – HAM:MMQ0 - TradingView
Price to sales forward of Definium Therapeutics, Inc. – HAM:MMQ0 - TradingView
Price to earnings forward of Definium Therapeutics, Inc. – NASDAQ:DFTX - TradingView
Price to book forward of Definium Therapeutics, Inc. – HAM:MMQ0 - TradingView
Price to earnings forward of Definium Therapeutics, Inc. – HAM:MMQ0 - TradingView
LifeSci Capital Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $63 - Moomoo
ETFs Investing in Definium Therapeutics, Inc. Stocks - TradingView
Price to earnings ratio of Definium Therapeutics, Inc. – HAM:MMQ0 - TradingView
Definium Therapeutics Prices Offering of Nearly 20.6M Shares at $34.00 Each >DFTX - Moomoo
Definium Therapeutics (DFTX) CLO sells 13,008 shares to cover RSU taxes - Stock Titan
Definium Therapeutics (DFTX) CMO sells 10,035 shares to cover RSU taxes - Stock Titan
Definium raises $805 million after positive Phase III depression data - The Pharma Letter
Definium Therapeutics, Inc. Announces Closing - Moomoo
Definium Therapeutics (DFTX) CFO disposes 3,013 shares to cover RSU taxes - Stock Titan
Form 144 DEFINIUM THERAPEUTICS For: 25 June By Investing.com - Investing.com South Africa
Definium Therapeutics prices $700M upsized public offering at $34.00 a share - MSN
Top Definium Therapeutics (DFTX) Competitors 2026 - MarketBeat
Definium Therapeutics, Inc. Announces Closing of $805 Million Upsized Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares - BioSpace
Definium Therapeutics closes $805 million stock offering - Investing.com UK
Definium Therapeutics Company Profile & Introduction - Moomoo
Definium Therapeutics, Inc. Actuals & Estimates (NASDAQ:DFTX) - TradingView
Definium Therapeutics Inc Stock (DFTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Definium Therapeutics Inc Stock (DFTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Roberts Brandi | Chief Financial Officer |
Jun 25 '26 |
Sale |
45.03 |
3,013 |
135,675 |
209,487 |
| Barrow Robert | Chief Executive Officer |
Jun 25 '26 |
Sale |
45.03 |
29,208 |
1,315,236 |
1,098,246 |
| Karlin Daniel | Chief Medical Officer |
Jun 25 '26 |
Sale |
45.03 |
10,035 |
451,876 |
503,282 |
| Wiley Matthew T. | Chief Commercial Officer |
Jun 25 '26 |
Sale |
45.03 |
2,867 |
129,101 |
174,633 |
1.17%
2.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):